HK Stock Market Move | KEYMED BIO-B (02162) Surges Over 12% as Kangyueda Revenue for the First Three Quarters Increased 227% Year-on-Year and New Indication Approved

KEYMED BIO-B (02162) surged over 12%, up 11.82% as of press time, at HK$85.15, with a turnover of HK$89.8682 million. On the news front, Keymed Biosciences announced that revenue from its product Kangyueda (IL-4R monoclonal antibody, stapokibart) totaled approximately RMB 660 million for the first three quarters of 2026, representing a year-on-year increase of approximately 227%, driven primarily by genuine market demand and a sharp increase in the number of hospitals with access. Meanwhile, China's National Medical Products Administration has recently approved the marketing application for a new indication of Kangyueda for the treatment of adolescent moderate-to-severe atopic dermatitis (AD), with both vial (300mg [2ml]/vial) and pre-filled autoinjector pen (300mg [2ml]/pen) packaging approved.